ebitda rose y-o-i top line segment
op growth amort rose y-o-i fcf/ebitda
consist recent year highest coverag far median
rang end net leverag ebitda robust
financi capac acquisit enthusiast note larg activ
pipelin qualiti acquisit focu remain platform-level deal
retain flexibl leverag short term current note undrawn
revolv organ outlook includ broad strength minor
offset energy/industri asid larg new transcor project callout includ
verathon bronchoscop launch traction scope expans deltek ader
adj ep rose beat consensus/
guidanc revenu grew y-o-i organ
acquisit vs estim segment om bp y-o-i top
estim ebitda margin rose bp
roper establish adjust ep guidanc prior consensu
organ growth adj ep guidanc
compar prior consensu organ
comparison mha industri energi busi mta project
revenu includ process segment outlook msd
applic softwar target healthi msd growth broad contribut
sunquest deltek ader strong mix market share gain new
applic outlook msd growth includ stronger industri
comp launch favor neptun still grow
network softwar system outlook mid-teen organ pair
ipipeline/foundri carryov start slower msd mha post
robust mta project ramp aggress past segment
incur real om pressur mha comp full year mta project mix
full year non-cash amort latest deal
maintain rais lift
pt base adj ep pt reflect
current fcf-per-share vs support highli probabl steadi
pace acquisit expect oper model consist support
fcf/ani time
year price histori
design develop softwar
engin product solut
varieti nich end-market includ
educ academ research
analyst certif import disclosur see disclosur
robust gener solid convers deal pipelin
remain attract long-term opportun steadi
persist organ growth serv market high-
qualiti portfolio busi rop strong posit
solid balanc sheet cash flow outlook allow
compound flexibl capit opportunist acquisit
upsid oper leverag softwar acquisit growth
larger deal past year look favor vs deal
acceler perform deal close cyclic exposur
process cyclic snap-back later cycl exposur
inabl execut deal flow expect
period close materi acquisit
pt target adj ep reflect current fcf-per-share vs support highli probabl
steadi pace acquisit impli upsid potenti includ dividend yield
risk achiev price target medic growth underperform toll busi lumpi pend slower deal flow
record deal activ notwithstand pay debt
exhibit segment result varianc opco estim
report adjust ep vs year ago compar
consensu guidanc adjust revenu grew y-o-i
organ acqs/div vs estim adjust segment margin bp y-o-
ebitda margin rose bp beat estim adjust gross margin widen
bp y-o-i
guidanc manag establish ep guidanc vs prior
consensu organ growth outlook excl transcor first-quart adjust ep
guidanc compar prior consensu
flow/bal sheet end cash net debt/capit vs
end gross leverag net leverag vs year-end
vs last year cfo/ani fcf/ani
applic softwar sale
revenu increas y-o-i organ acquisit vs estim
strength across group adjust om expand bp compar
manag expect continu mid-singl digit organ growth segment momentum
double-digit expans deltek acv book
network softwar system sale
revenu rose y-o-i organ acquisit vs estim
softwar busi rose organ transcor project time adjust om
contract bp match estim
manag expect mid-teen digit organ growth msd transcor nyc project
strength softwar msd
measur analyt solut sale
revenu decreas y-o-i organ divestitur match estim organ
reflect growth neptun medic product busi short cycl industri
declin om expand bp beat estim
manag expect mid-singl digit organ growth stronger base
comparison industri relat busi
process technolog sale
revenu fell y-o-i organ fx vs estim declin upstream
 om contract bp y-o-i edg estim
manag expect organ revenu mid-singl digit weak outlook upstream
 though comparison eas
annual sale profit segment
earn continu oper
loss discontinu operations/oth
compani report oppenheim co inc estim
quarterli sale profit segment
earn continu oper
loss disc ops/oth adj
compani report oppenheim co inc estim
analysi oper
segment revenu
total segment revenu
segment profit
total segment profit
compani report oppenheim co inc estim
year end decemb million
good sold
earn continu oper
loss discontinu operations/oth
compani report oppenheim co inc estim
sale
earn continu oper
loss disc ops/oth adj
year end decemb million
current portion long term debt
average day inventori day hand
compani report oppenheim co inc estim
consolid statement flow
year end decemb million
depreci pp
goodwil transit impair net tax
dispos busi
net chang work capit
busi acquisit net acquir
proce note payabl lt debt
princip pmt note payabl lt debt
issuanc common stock
increas dec
equival -b
equival -e
compani report oppenheim co inc estim
